Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study
暂无分享,去创建一个
D. Kyle | F. Nosten | P. Singhasivanon | W. Ballou | D. Gordon | D. Heppner | C. Luxemburger | J. Sadoff | J. Blood | T. Chongsuphajaissidhi
[1] Ballou Wp. Clinical trials of Plasmodium falciparum erythrocytic stage vaccines. , 1994 .
[2] P. Alonso,et al. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia , 1993, The Lancet.
[3] G. Campbell,et al. Immunogenicity of the Plasmodium falciparum asexual blood-stage synthetic peptide vaccine SPf66. , 1993, The American journal of tropical medicine and hygiene.
[4] G. Targett. SPf66, a candidate synthetic malaria vaccine: Immunogenicity versus protection. , 1992, Parasitology today.
[5] A. Mora,et al. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. , 1992, The Journal of infectious diseases.
[6] A. Moreno,et al. Determination of the immunization schedule for field trials with the synthetic malaria vaccine SPf 66 , 1992, Parasite immunology.
[7] B. Knapp,et al. A Plasmodium falciparum blood stage antigen highly homologous to the glycophorin binding protein GBP. , 1991, Molecular and biochemical parasitology.
[8] M. Patarroyo,et al. Specific interactions of synthetic peptides derived from P. falciparum merozoite proteins with human red blood cells. , 1991, Peptide research.
[9] M. Patarroyo,et al. Studies on the humoral immune response to a synthetic vaccine against Plasmodium falciparum malaria , 1991, Clinical and experimental immunology.
[10] A. Moreno,et al. Studies in owl monkeys leading to the development of a synthetic vaccine against the asexual blood stages of Plasmodium falciparum. , 1990, The American journal of tropical medicine and hygiene.
[11] Pedro Romero,et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria , 1988, Nature.
[12] P. Romero,et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides , 1987, Nature.
[13] J. Moscoso,et al. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. , 1994, Vaccine.
[14] M. Tanner,et al. A trial of the synthetic malaria vaccine SPf66 in Tanzania: rationale and design. , 1994, Vaccine.
[15] P. Alonso,et al. Characterization of SPf(66)n: a chimeric molecule used as a malaria vaccine. , 1994, Vaccine.
[16] T. Smith,et al. SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission. , 1994, Vaccine.
[17] W. R. Ballou. Clinical trials of Plasmodium falciparum erythrocytic stage vaccines. , 1994, American Journal of Tropical Medicine and Hygiene.
[18] M. Patarroyo,et al. Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years. , 1992, Vaccine.
[19] F. Gúzman,et al. The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity. , 1992, Vaccine.
[20] L Molineaux,et al. Estimation of incidence and recovery rates of Plasmodium falciparum parasitaemia from longitudinal data. , 1976, Bulletin of the World Health Organization.